The evolution of lipid-lowering drugs in the management of cardiovascular risk: from the first cardiovascular risk reducing therapies to the novel challenging strategies
1. 请及时下载文件确认是否正确, 系统将在 2025-12-21 21:22:22 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: https://pubmed.ncbi.nlm.nih.gov/40945405/
其他信息:
D Henry, E Baugé, B Staels, F Lalloyer
Pharmacological Reviews, 2025
Elsevier
ABSTRACT Before the Framingham Heart Study, the concept of cardiovascular risk factors did not exist and cardiovascular diseases (CVD) were seen as a consequence of aging. The first two reports in 1957 and 1961 identified high cholesterol levels as a major risk factor for CVD, highlighting the importance of lipid management to reduce CVD risk. Since then, the growing knowledge of CVD pathophysiology led to the development of many drug classes to manage dyslipidemia and consequently cardiovascular risk. Unfortunately, many of them …
